Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - Mass Medical Soc
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
[PDF][PDF] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
G Saglio, DW Kim, S Issaragrisil, P le Coutre… - N Engl J …, 2010 - researchgate.net
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
[引用][C] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - researchportal.helsinki.fi
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia — University of
Helsinki Skip to main navigation Skip to search Skip to main content University of Helsinki …
Helsinki Skip to main navigation Skip to search Skip to main content University of Helsinki …
[PDF][PDF] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
G Saglio, DW Kim, S Issaragrisil… - N Engl J …, 2010 - mauriciolema.webhost4life.com
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
G Saglio, DW Kim, S Issaragrisil, P le Coutre… - New England Journal …, 2010 - elibrary.ru
BACKGROUND Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil… - The New England …, 2010 - pubmed.ncbi.nlm.nih.gov
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
[引用][C] Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G SAGLIO - N Engl J Med., 2010 - cir.nii.ac.jp
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF][PDF] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
G Saglio, DW Kim, S Issaragrisil, P le Coutre, G Etienne… - 2010 - phdres.caregate.net
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
G Saglio, D Kim, S Issaragrisil, P le Coutre… - NEW ENGLAND …, 2010 - iris.uniroma1.it
BACKGROUND: Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
[PDF][PDF] Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
G Saglio, DW Kim, S Issaragrisil, P le Coutre, G Etienne… - 2010 - academia.edu
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …